Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Simpson, E.L., Sinclair, R., Forman, S. et al. (14 more authors) (2020) Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet, 396 (10246). pp. 255-266. ISSN 0140-6736

Abstract

Metadata

Authors/Creators:
  • Simpson, E.L.
  • Sinclair, R.
  • Forman, S.
  • Wollenberg, A.
  • Aschoff, R.
  • Cork, M. ORCID logo https://orcid.org/0000-0003-4428-2428
  • Bieber, T.
  • Thyssen, J.P.
  • Yosipovitch, G.
  • Flohr, C.
  • Magnolo, N.
  • Maari, C.
  • Feeney, C.
  • Biswas, P.
  • Tatulych, S.
  • Valdez, H.
  • Rojo, R.
Copyright, Publisher and Additional Information: © 2020 Elsevier Ltd. This is an author produced version of a paper subsequently published in The Lancet. Uploaded in accordance with the publisher's self-archiving policy. Article available under the terms of the CC-BY-NC-ND licence (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Administration, Oral; Adolescent; Adult; Aged; Australia; Canada; Case-Control Studies; Child; Dermatitis, Atopic; Double-Blind Method; Eczema; Ethnic Groups; Europe; Female; Humans; Janus Kinase 1; Male; Middle Aged; Placebos; Protein Kinase Inhibitors; Pyrimidines; Safety; Severity of Illness Index; Sulfonamides; Treatment Outcome; United States
Dates:
  • Published (online): 23 July 2020
  • Published: 25 July 2020
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 09 Sep 2020 15:26
Last Modified: 23 Jan 2021 01:39
Status: Published
Publisher: Elsevier BV
Refereed: Yes
Identification Number: https://doi.org/10.1016/s0140-6736(20)30732-7
Related URLs:

Share / Export

Statistics